Pune, India -- (SBWIRE) -- 05/07/2019 -- The Global Pharmacovigilance Market Size is estimated to grow at CAGR above 12.8 % over the forecast time frame 2019-2026 and reach the market value around USD 10.6 billion by 2026.

The main factors driving growth in emerging economies are increasing female employment, various government actions aimed at increasing consumer awareness and improving health infrastructure. An increasing number of women's jobs is expected to be a driving force on the market. Working women are expected to have a comparatively higher disposable income and a shorter breastfeeding time to feed babies. For example, the employment rate for women has increased from 65% in 2016 to 66% in 2017, according to Eurostat. Working women find it difficult to provide their babies with a proper diet, leading to an increase in neonatal death. Pharmacovigilance in such cases enable mothers to provide their babies with proper nutrition without impeding their working lives.

Free Download Sample Report Pages for Better Understanding@ https://www.acumenresearchandconsulting.com/request-sample/1331

In addition, the product demand may be raised by favorable health insurance plans. The majority of health plans require consumers to buy specific brand Pharmacovigilance. Manufacturers therefore cooperate with insurance companies to increase the market presence and market shares of these companies and thus stimulate growth in the market for Pharmacovigilance.

End Use

Hospitals held the largest share in revenue on the market in 2018. Hospitals serve the regulatory authorities to verify the necessity for post-marketing surveillance in reporter organisations, which have reported ADRs within a certain period. Increased ADR incidence and medication mistakes are expected to increase the growth of the hospital segment during the prediction period. The growing need to identify risks related to ADRs is expected further to boost segment growth in the coming years.

Research organizations include primarily medical information centres, research academics, pharmacovigilance centers and players from industry. These organizations detect, examine, assess patterns, report ADRs and also examine the potential interactions between drugs and food. Research organisations, owing to the increasing need to investigate ADRs and to develop remedial medicinal treatment, to give regulatory authorities safety signals and to increase awareness among the patient base, are expected to show lucrative growth in forecast period. The growing need for the regulatory authorities to provide medical information will also drive the growth of this segment.

Type of Methods Outlook

Due to the wide use in identifying new, serious, rarity ADRs, the spontaneous reporting was the most significant market share in 2018 and acts as an effective and inexpensive method. The significant market portion of spontaneous reporting is also accountable for the large use of the surveillance reports generated by the pharmaceutical and regulatory industries through this method.

CEM is expected to be the fastest growing segment due to the increasing application of Cohort Event Monitoring in the detection of a wide range of clinical events. The increasing popularity of this segment is responsible for the combination of CEM with statistical instruments and data mining systems namely longitudinal health data. It is an active form of monitoring method that can also be used to stimulate growth in this area for new and former medicines.

View Detail Information with Complete TOC@ https://www.acumenresearchandconsulting.com/pharmacovigilance-market

The targeted spontaneous reporting of the European Network of Centers of Pharmacoepidemiology and Pharmacovigilance (ENCePp) is anticipated to show significant growth in the near future due to rising government initiatives incorporating reporting methodology, other than spontaneous reporting. The benefits of targeted spontaneous reporting such as higher affordability, lower labor costs, feasibility in poor resource environments, and routine monitoring should further boost the market.

Increasingly, electronic health record (her) mining is being used to identify patient risk factors after hospital release. In hospitals and research organisations, electronic health records are an indispensable source of health information relating to clinical events. Over the forecast period the segment will be fuel-filled for the benefits of HER, including enhanced quality of care, automated access, clinical decision-making, and patient management and improved clinical workflow.

Key Players & Strategies

The Pharmacovigilance market is consolidated with large number of manufacturers. The company profiling of key players in the market includes major business strategies, company overview and revenues. The key players of the market are Clinquest Group, IBM Corporation, ArisGlobal, ICON plc. Accenture, Clinquest Group B.V., Cognizant, Laboratory Corporation of America Holdings. TAKE Solutions Ltd., PAREXEL International Corporation, BioClinica, Wipro Ltd. and United BioSource Corporation, Capgemini, iMEDGlobal, Foresight Group International AG., among others.

Browse All official Market Research Reports Press Releases@ https://www.acumenresearchandconsulting.com/press-releases

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Pharmacovigilance
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Pharmacovigilance Market By Clinical Trial Phase
1.2.2.1. Global Pharmacovigilance Market Revenue and Growth Rate Comparison By Clinical Trial Phase (2015-2026)
1.2.2.2. Global Pharmacovigilance Market Revenue Share By Clinical Trial Phase in 2017
1.2.2.3. Pre-clinical
1.2.2.4. Phase I
1.2.2.5. Phase II
1.2.2.6. Phase III
1.2.2.7. Phase IV
1.2.3. Pharmacovigilance Market By Service
1.2.3.1. Global Pharmacovigilance Market Revenue and Growth Rate Comparison By Service (2015-2026)
1.2.3.2. Global Pharmacovigilance Market Revenue Share By Service in 2017
1.2.3.3. In-house
1.2.3.4. Contract Outsourcing
1.2.4. Pharmacovigilance Market By Type
1.2.4.1. Global Pharmacovigilance Market Revenue and Growth Rate Comparison By Type (2015-2026)
1.2.4.2. Global Pharmacovigilance Market Revenue Share By Type in 2017
1.2.4.3. Spontaneous Reporting
1.2.4.4. Intensified ADR Reporting
1.2.4.5. Targeted Spontaneous Reporting
1.2.4.6. Cohort Event Monitoring
1.2.4.7. EHR Mining
1.2.5. Pharmacovigilance Market By End Use
1.2.5.1. Global Pharmacovigilance Market Revenue and Growth Rate Comparison By End Use (2015-2026)
1.2.5.2. Global Pharmacovigilance Market Revenue Share By End Use in 2017
1.2.5.3. Hospitals
1.2.5.4. Research Organizations
1.2.5.5. Industrial
1.2.6. Pharmacovigilance Market by Geography
1.2.6.1. Global Pharmacovigilance Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.6.2. North America Pharmacovigilance Market Revenue and Growth Rate (2015-2026)
1.2.6.3. Europe Pharmacovigilance Market Revenue and Growth Rate (2015-2026)
1.2.6.4. Asia-Pacific Pharmacovigilance Market Revenue and Growth Rate (2015-2026)
1.2.6.5. Latin America Pharmacovigilance Market Revenue and Growth Rate (2015-2026)
1.2.6.6. Middle East and Africa (MEA) Pharmacovigilance Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter's Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Pharmacovigilance Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Pharmacovigilance Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Pharmacovigilance Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Pharmacovigilance Major Manufacturers in 2017

CHAPTER 4. Pharmacovigilance Market By Clinical Trial Phase

4.1. Global Pharmacovigilance Revenue By Clinical Trial Phase
4.2. Pre-clinical
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Phase I
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Phase II
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Phase III
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.6. Phase IV
4.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. Pharmacovigilance Market By Service

5.1. Global Pharmacovigilance Revenue By Service
5.2. In-house
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Contract Outsourcing
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. Pharmacovigilance Market By Type

6.1. Global Pharmacovigilance Revenue By Type
6.2. Spontaneous Reporting
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Intensified ADR Reporting
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Targeted Spontaneous Reporting
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.5. Cohort Event Monitoring
6.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.6. EHR Mining
6.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 7. Pharmacovigilance Market By End Use

7.1. Global Pharmacovigilance Revenue By End Use
7.2. Hospitals
7.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.3. Research Organizations
7.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.4. Industrial
7.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 8. North America Pharmacovigilance Market By Country

8.1. North America Pharmacovigilance Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. North America Pharmacovigilance Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. U.S.
8.3.1. U.S. Pharmacovigilance Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
8.4. Canada
8.4.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
8.5. Mexico
8.5.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)

CHAPTER 9. Europe Pharmacovigilance Market By Country

9.1. Europe Pharmacovigilance Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Europe Pharmacovigilance Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. UK
9.3.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
9.4. Germany
9.4.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
9.5. France
9.5.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
9.6. Spain
9.6.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
9.7. Rest of Europe
9.7.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)

CHAPTER 10. Asia-Pacific Pharmacovigilance Market By Country

10.1. Asia-Pacific Pharmacovigilance Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Asia-Pacific Pharmacovigilance Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. China
10.3.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
10.4. Japan
10.4.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
10.5. India
10.5.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
10.6. Australia
10.6.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
10.6.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
10.7. South Korea
10.7.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
10.7.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
10.8. Rest of Asia-Pacific
10.8.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
10.8.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)

CHAPTER 11. Latin America Pharmacovigilance Market By Country

11.1. Latin America Pharmacovigilance Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Latin America Pharmacovigilance Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. Brazil
11.3.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
11.4. Argentina
11.4.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
11.5. Rest of Latin America
11.5.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)

CHAPTER 12. Middle East Pharmacovigilance Market By Country

12.1. Middle East Pharmacovigilance Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Middle East Pharmacovigilance Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. Saudi Arabia
12.3.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
12.4. UAE
12.4.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
12.5. Rest of Middle East
12.5.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)

CHAPTER 13. Africa Pharmacovigilance Market By Country

13.1. Africa Pharmacovigilance Market Revenue and Growth Rate, 2015 - 2026 ($Million)
13.2. Africa Pharmacovigilance Market Revenue Share Comparison, 2015 & 2026 (%)
13.3. South Africa
13.3.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
13.3.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
13.4. Egypt
13.4.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
13.4.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)
13.5. Rest of Africa
13.5.1. Market Revenue and Forecast By Clinical Trial Phase, 2015 - 2026 ($Million)
13.5.2. Market Revenue and Forecast By Service, 2015 - 2026 ($Million)

CHAPTER 14. COMPANY PROFILE

14.1. Clinquest Group
14.1.1. Company Snapshot
14.1.2. Overview
14.1.3. Financial Overview
14.1.4. Product Portfolio
14.1.5. Key Developments
14.1.6. Strategies
14.2. IBM Corporation
14.2.1. Company Snapshot
14.2.2. Overview
14.2.3. Financial Overview
14.2.4. Product Portfolio
14.2.5. Key Developments
14.2.6. Strategies
14.3. ArisGlobal
14.3.1. Company Snapshot
14.3.2. Overview
14.3.3. Financial Overview
14.3.4. Product Portfolio
14.3.5. Key Developments
14.3.6. Strategies
14.4. ICON plc.
14.4.1. Company Snapshot
14.4.2. Overview
14.4.3. Financial Overview
14.4.4. Product Portfolio
14.4.5. Key Developments
14.4.6. Strategies
14.5. Accenture
14.5.1. Company Snapshot
14.5.2. Overview
14.5.3. Financial Overview
14.5.4. Product Portfolio
14.5.5. Key Developments
14.5.6. Strategies
14.6. Clinquest Group B.V.
14.6.1. Company Snapshot
14.6.2. Overview
14.6.3. Financial Overview
14.6.4. Product Portfolio
14.6.5. Key Developments
14.6.6. Strategies
14.7. Cognizant
14.7.1. Company Snapshot
14.7.2. Overview
14.7.3. Financial Overview
14.7.4. Product Portfolio
14.7.5. Key Developments
14.7.6. Strategies
14.8. Laboratory Corporation
14.8.1. Company Snapshot
14.8.2. Overview
14.8.3. Financial Overview
14.8.4. Product Portfolio
14.8.5. Key Developments
14.8.6. Strategies
14.9. TAKE Solutions Ltd.
14.9.1. Company Snapshot
14.9.2. Overview
14.9.3. Financial Overview
14.9.4. Product Portfolio
14.9.5. Key Developments
14.9.6. Strategies

14.10. PAREXEL International Corporation

14.10.1. Company Snapshot
14.10.2. Overview
14.10.3. Financial Overview
14.10.4. Product Portfolio
14.10.5. Key Developments
14.10.6. Strategies
14.11. BioClinica
14.11.1. Company Snapshot
14.11.2. Overview
14.11.3. Financial Overview
14.11.4. Product Portfolio
14.11.5. Key Developments
14.11.6. Strategies
14.12. Wipro Ltd.
14.12.1. Company Snapshot
14.12.2. Overview
14.12.3. Financial Overview
14.12.4. Product Portfolio
14.12.5. Key Developments
14.12.6. Strategies
14.13. United BioSource Corporation
14.13.1. Company Snapshot
14.13.2. Overview
14.13.3. Financial Overview
14.13.4. Product Portfolio
14.13.5. Key Developments
14.13.6. Strategies
14.14. Capgemini
14.14.1. Company Snapshot
14.14.2. Overview
14.14.3. Financial Overview
14.14.4. Product Portfolio
14.14.5. Key Developments
14.14.6. Strategies
14.15. iMEDGlobal
14.15.1. Company Snapshot
14.15.2. Overview
14.15.3. Financial Overview
14.15.4. Product Portfolio
14.15.5. Key Developments
14.15.6. Strategies
14.16. Foresight Group International AG.
14.16.1. Company Snapshot
14.16.2. Overview
14.16.3. Financial Overview
14.16.4. Product Portfolio
14.16.5. Key Developments
14.16.6. Strategies
14.17. Others
14.17.1. Company Snapshot
14.17.2. Overview
14.17.3. Financial Overview
14.17.4. Product Portfolio
14.17.5. Key Developments
14.17.6. Strategies

CHAPTER 15. RESEARCH APPROACH

15.1. Research Methodology
15.1.1. Initial Data Search
15.1.2. Secondary Research
15.1.3. Primary Research
15.2. Assumptions and Scope

INQUIRY BEFORE BUYING@ https://www.acumenresearchandconsulting.com/inquiry-before-buying/1331

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this Premium Research Report - https://www.acumenresearchandconsulting.com/buy-now/0/1331

Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157

About Acumen Research and Consulting:
Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.